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ABSTRACT: Advances in DNA sequencing technology facilitate investigating the impact of rare variants on complex diseases.
However, using a conventional case-control design, large samples are needed to capture enough rare variants to achieve
sufficient power for testing the association between suspected loci and complex diseases. In such large samples, population
stratification may easily cause spurious signals. One approach to overcome stratification is to use a family-based design. For
rare variants, this strategy is especially appropriate, as power can be increased considerably by analyzing cases with affected
relatives. We propose a novel framework for association testing in affected sibpairs by comparing the allele count of rare
variants on chromosome regions shared identical by descent to the allele count of rare variants on nonshared chromosome
regions, referred to as test for rare variant association with family-based internal control (TRAFIC). This design is generally
robust to population stratification as cases and controls are matched within each sibpair. We evaluate the power analytically
using general model for effect size of rare variants. For the same number of genotyped people, TRAFIC shows superior power
over the conventional case-control study for variants with summed risk allele frequency f < 0.05; this power advantage
is even more substantial when considering allelic heterogeneity. For complex models of gene-gene interaction, this power
advantage depends on the direction of interaction and overall heritability. In sum, we introduce a new method for analyzing
rare variants in affected sibpairs that is robust to population stratification, and provide freely available software.
Genet Epidemiol 39:325–333, 2015. © 2015 Wiley Periodicals, Inc.
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Introduction
Rare variants with large relative risk are hypothesized to
explain some of the missing heritability of complex dis-
eases [Manolio et al., 2009]. Several studies have identified
rare variants underlying rare Mendelian diseases using next-
generation sequencing technology [Ng et al., 2010; Ng et al.,
2009].However, the conventional case-control design has low
statistical power to detect the association between rare vari-
ants and complex diseases [Cooper and Shendure, 2011; Li
and Leal, 2008]. To overcome the low power of single-marker
test on rare variants, researchers have proposed to combine
variants in a gene or genomic region to test for association
[Li and Leal, 2008; Price et al., 2010; Zawistowski et al., 2014].
However, such gene-based tests in population samples may
still need >10,000 individuals to identify the signal from rare
variants [Nelson et al., 2012]; sequencing such large samples
is still very expensive. Moreover, large samples are typically
more heterogeneous in origin, increasing the risk of popu-
lation stratification [Price et al., 2006]. In such large sam-
ples, even subtle stratification causes substantially increased
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false-positive rate in rare variant tests [Zawistowski et al.,
2014]. Although methods to control for population stratifi-
cation, such as principal components and genomic control
[Devlin and Roeder, 1999; Price et al., 2006], have been suc-
cessfully applied for common variants, it is unclear whether
suchmethods are appropriate for rare variant tests [Liu,Nico-
lae and Chen, 2013; Mathieson and McVean, 2012].
As familymembers are naturallymatched for genetic back-
ground, several recent gene-basedmethods for testing the as-
sociationbetween rare variants and thephenotype adapt fam-
ilydata to control forpopulation stratification [Deet al., 2013;
Guo and Shugart, 2012]. In addition, the allele frequency of
rare risk variants in cases can be substantially increased by
collecting cases with affected relatives [Fingerlin et al., 2004;
Peng et al., 2010; Zo¨llner, 2012]. Although collecting families
with multiple affected members is challenging, family-based
studies of rare variants can leverage existing large collections
of families that were originally generated for linkage analysis
[Guan et al., 2012; Howson et al., 2009; Rao et al., 2003];
for example, International Type 2 Diabetes Linkage Analysis
Consortium contains >4,000 affected sibpairs [Guan et al.,
2012].
Methods have been proposed to extend the current col-
lapsing tests to rare variants in family data. Guo and Shugart
[2012] and De et al. [2013], extended the family-based
C© 2015 WILEY PERIODICALS, INC.
association test (FBAT) [Laird and Lange, 2006] to rare vari-
ants in the style of a collapsing test. Schifano et al. 2012 and
Chen et al. 2013 used linearmixedmodels to extend the SNP-
set kernel association test (SKAT) [Wuet al., 2011] to families.
Shugart et al. [2012] and Fang et al. [2012] proposed to es-
timate the relatedness between samples and adjust the test
statistics for rare variant association accordingly. However,
none of the existing methods directly leverage the benefit
of studying families where the same rare variant is observed
multiple times. By using such information, we can increase
power to detect the association between rare variants and the
phenotype.
Here, we propose a powerful framework for testing rare
variant associations using affected sibpairs. We create a
matched design by comparing the allele count of rare vari-
ants on shared identity by descent (IBD) chromosome re-
gions to the allele count on nonshared identity by descent
chromosome regions across affected sibpairs in a region of
interest. Sharing status of chromosome regions can be eas-
ily estimated using high-density genotype data [Keith et al.,
2008], and sharing status of alleles can be inferred condi-
tional on the known chromosome region sharing status. In-
tuitively, we consider shared chromosome regions as “case”
chromosome regions and nonshared chromosome regions as
“control” chromosome regions. Under the null hypothesis
of no association, the probability of a shared chromosome
region carrying an allele is identical to the probability of a
nonshared chromosome region carrying an allele. Under the
alternative that an allele increases/decreases the disease risk,
the probability of a shared chromosome region carrying that
allele is higher/lower than the probability of a nonshared
chromosome region carrying that allele.
We evaluate this design by calculating the analytical power
for a collapsing gene-based test [Li and Leal, 2008], assum-
ing a general model of rare risk alleles that is specified by
the summed allele frequency of all rare risk variants in the
gene and the mean and variance of their effect size [Zo¨llner,
2012]. We show that given the same number of sequenced
individuals, the power of the proposed affected sibpair test
for rare variant association with family-based internal con-
trol (TRAFIC) is higher than the conventional case-control
design for rare risk variants (summed risk allele frequency
< 0.05). Considering allelic heterogeneity, where risk vari-
ants have different effect sizes, TRAFIC doubles the power
of a case-control study in many realistic parameter values.
We also evaluate the power of the proposed method under
various gene-gene interactionmodels andfind that power de-
pends on the type of interaction and the overall heritability of
thedisease.Using simulations,wealso showthat theproposed
TRAFIC is generally robust to population stratification.
Materials and Methods
TRAFIC
We consider a set of affected sibpairs with known number
of chromosome regions shared identical by descent (IBD).
Table 1. Identification of variant IBD status conditional on chro-
mosome region IBD status
0 IBD
chromosome
region
1 IBD
chromosome
region
2 IBD
chromosome
regions
Both siblings are
homozygous
minor allele
Four nonshared
alleles
One shared and
2 nonshared
alleles
Two shared
alleles
One homozygous
minor allele and
one heterozygote
Three nonshared
alleles
One shared and
1 nonshared
alleles
N/A
Both siblings are
heterozygous
Two nonshared
alleles
Ambiguous
configuration
One shared allele
Assuming chromosome region IBD status is known, the number of shared and
nonshared alleles can be inferred for all but one configuration of genotypes (shaded
cell).
At a locus of interest (e.g., a gene), we compare the count of
alleles of rare variants on chromosome regions shared IBD
between the siblings to the count of alleles of rare variants on
chromosome regions not shared IBD (non-IBDchromosome
regions) across sibpairs. Let, p IBD be the frequency of IBD
chromosome region carrying at least one allele and pNonIBD
be the frequency of non-IBD chromosome regions carrying
at least one allele. Alleles without effect on disease risk are
equally likely to occur on any chromosome region regard-
less of IBD status. Thus, the null hypothesis under no asso-
ciation is H0 : p IBD = pNonIBD . Variants that are associated
with the phenotype (protective or causative) would differ in
frequency between IBD and non-IBD chromosome regions.
Hence, we can test for departure from the null hypothesis ei-
ther in a collapsing framework by considering the alternative
Ha : p IBD =pNonIBD or in a dispersion framework where this
alternative is considered for each variant and the combined
test statistic aggregates the evidence across all variants.
In a sibpair with known IBD status, identifying whether
an allele of a variant is located on an IBD or a non-IBD
chromosome region is straightforward formost genotypes as
shown in Table 1; for example, when a sibpair does not share
the chromosome region (0 IBD chromosome region), all ob-
served alleles for that variant in two siblings are nonshared;
for a sibpair who shares 1 IBD chromosome region, the alleles
of a homozygous sibling must be one shared and one non-
shared. Only when the sibpair shares one IBD chromosome
region and the genotypes are heterozygous in both individu-
als, the IBD status of the allele is ambiguous (shaded in Table
1): this configuration could be either the result of a single
rare allele located on the IBD chromosome region or two
copies of the rare allele inherited separately on the non-IBD
chromosome regions (as illustrated in supplementary Ap-
pendix Fig. S1). To resolve this ambiguous configuration, we
implement an imputation algorithm and use simulations to
show the false-positive rate is controlled (see supplementary
Appendix 1 for details).
Evaluating TRAFIC
The analytical power of the proposed TRAFIC based on a
collapsing gene-based test depends on the difference between
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the expected allele count on shared IBD chromosome regions
and the expected allele count on nonshared IBD chromo-
some regions. To calculate these expectations, we assume
that all rare variants evaluated in a locus occur on different
haplotypes. Let f be the sum of population allele frequencies
of all risk variants (summed risk allele frequency). For each
sibpair, we count the number of alleles HS ∈ {0, 1, 2} on
the shared chromosome regions and the number of alleles
HNS ∈ {0, 1, 2, 3, 4} on nonshared chromosome regions.
Let AAR be an affected sibpair and P(HS ,HNS |AAR , S) be
the probability of HS , HNS conditional on the number of
shared IBD chromosome regions S ∈ {0, 1, 2}. Using Bayes’
rule, we can write this conditional probability as
P (HS ,HNS |AAR , S) = P (AAR|HS ,HNS) P (HS ,HNS |S)
×P (S) 1
P (AAR , S)
,
where P(AAR |HS ,HNS) depends on the underlying genetic
and effect size model (see supplementary Appendix 2 for
derivations). Based on previous work [Zo¨llner, 2012], we
model the effect size (relative risk) of each risk haplotype as a
random variable with the first twomomentsμ and σ2. Then,
P(HS ,HNS |AAR , S) is fully determined by the parametersμ,
σ2, and f (see supplementary Appendix 2). We calculate the
power for TRAFIC based on P(HS ,HNS |AAR , S) for a range
of relative risk parameter μ and σ2, and under different f
assuming a simple collapsing method [Li and Leal, 2008] to
test the association between rare variants and the dichoto-
mous phenotype (supplementary Appendix 3). To maintain
an overall false-positive rate of 0.05 after testing 20,000 genes
in the genome, we set the false-positive rate to 2.5 × 10–6.
We compare our proposed TRAFIC with two other designs:
(1) the conventional case-control study comparing a sample
of cases to unaffected controls. (2) A selected cases design
comparing cases that are ascertained to have an affected
sibling to unaffected controls [Fingerlin et al., 2004, Zo¨llner,
2012]. All designs retain the nominal false-positive rate
under the null (supplementary Appendix Table S1).
Simulation Setup for TRAFIC
To validate the derived analytical results, we simulate sib-
pair samples and apply our proposedTRAFIC.Wefirst gener-
ate four independentparental haplotypes, each carrying a risk
allele with probability f.Without considering recombination,
we then generate two descendants, each randomly inheriting
one chromosome region from each parent. Following Risch
[1990], we define the contribution to prevalence K at the lo-
cus of interest as KL and the contribution of the remaining
genome as KG . The prevalence among subjects with an af-
fected relative with relation status R is KR ; the contribution
to KR at the locus of interest and the remaining genome are
then KLR and KGR , respectively. We adjust KGKGR under
the multiplicative model to maintain both K and the sibling
relative risk (SRR).
SRR =
KLKLRKGKGR
K × K .
Here KLKLR depends on P(AAR |HS ,HNS) (more details
in supplementary Appendix 2). The relative risk of the risk
allele follows a gamma distribution with specified μ and σ2.
Thus, the probability of having both siblings in the family
affected is KLKLRKGKGR and is set to 1 if the simulated
probability exceeds 1. We generate datasets of 1,000 affected
sibpairs in each replicate. To evaluate the performance of
our multiple imputation algorithm, we generate sibpairs as-
suming the sharing status is known. Then, we mask the true
location for the double-heterozygote sibpairs who share one
IBD chromosome region and apply our multiple imputation
algorithm.
Population Stratification
Using the simulation design described above, we evalu-
ate the impact of population stratification. We simulate two
populations with summed risk allele frequency of 0.01 and
0.05, respectively, and assign a ratio of prevalence π between
two populations. Assuming two populations have the same
sibling relative risk, the ratio of frequencies of affected sib-
pairs between the two populations is then π2. Assuming
that both populations contribute equally, we generate case-
control samples by sampling 1,000 cases, a proportion of
π/(1 + π) from population 1 and 1/(1 + π) from population
2. We also sample 1,000 controls with equal contribution
from each population. To generate a stratified sample for
TRAFIC, we generate a sample of 1,000 affected sibpairs
with a proportion of π2/(1 + π2) from population 1 and a
proportion of 1/(1 + π2) from population 2. We assume un-
known sharing status for double-heterozygote sibpairs who
share one IBD chromosome region and impute the sharing
status through multiple imputation. To generate cases for
the selected cases design, we sample affected sibpairs with a
proportion of π2/(1 + π2) from population 1 and 1/(1 + π2)
from population 2; controls are sampled evenly from both
populations. We generate 1,000 datasets for each value of π
and estimate the false-positive rate.
Gene-Gene Interaction
Interaction between the locus of interest and the remaining
genome can influence the power of association tests in family
samples [Risch, 2001; Zo¨llner, 2012].Wemodel gene-genome
interaction as two loci, L andG. L is the locus of interest, while
G represents genetic effects in the remainder of the genome.
We define the joint effect as
P (A |hm, hn, g s, g t) ∝ βhm+hnL βg s+g tG γ(hm+hn)(g s+g t).
wherehm andhn represent the indicator of a risk allele at locus
L; let g s and g t represent the indicator of a risk allele at locusG.
In the absence of risk alleles at G, all risk alleles at locus L have
the same relative risk βL . Moreover, we describe the extent of
interaction in this model by the parameter γ as the relative
risk when risk alleles are present at both loci L and G, where
γ = 1 indicates no interaction, γ < 1 indicates antagonistic
interaction, and γ > 1 indicates synergistic interaction.
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Under this model, the marginal relative risk at locus L is
P (A |hm = 1)
P (A |hm = 0)
=
βL
∑
hn
β
hn
L ρ(hn)
∑
gs
∑
g t
(βGγ)
g s+g tγhn(g s
+g t)p (g s)p (g t)
∑
hn
β
hn
L ρ(hn)
∑
g s
∑
g t
β
g s+g t
G γ
hn(g s+g t)p (g s)p (g t)
.
Themarginal relative risk at locusG is expressed in a similar
fashion. To explore the effect of gene-gene interaction, given
the sibling relative risk,wevaryγwhile adjustingβL andβG to
keep the marginal relative risks constant (see supplementary
Appendix 4). Thismaintains a constant power for the conven-
tional case-control study.We then calculate P(HS ,HNS |AAR)
at locus L and evaluate the power of TRAFIC for different
values of γ.
An Example to Illustrate TRAFIC
To illustrate how to apply TRAFIC, we simulate 1,000 sib-
pairs assuming the number of shared IBD chromosome re-
gion is known.We simulate sequence data by using coalescent
model based simulator COSI [Schaffner et al., 2005] to gen-
erate a population of ten thousand 1 kb haplotypes. From
the 50 variants in the region, we randomly pick 10 variants
with minor allele frequency (MAF) < 0.05 and assign each
variant the relative risk as a function of MAF, –log10(MAF)
[Wu et al., 2011]. In this setting, a variant with MAF = 0.05
has relative risk of 1.33 and a singleton has relative risk of
4. We thus generated a population with f = 0.025, μ = 2.52,
and σ2 = 0.62. We then generate 1,000 affected sibpairs and
apply TRAFIC to that dataset.
The simulated data contain 254, 509, and 237 sibpairs
who share 0, 1, and 2 chromosome regions, respectively;
these equal to 983 shared chromosome regions and 2,034
nonshared chromosome regions. Excluding 42 sibpairs who
shared one chromosome region with ambiguous double-
heterozygote genotypes, there are 51 shared and67nonshared
chromosome regions carrying at least one allele (carrier).
Using imputation to resolve the IBD status of allele from 42
sibpairs with ambiguous double-heterozygote genotypes, the
mean count of carrier chromosome regions is 91.7 on shared
chromosome regions and 67.6 on nonshared chromosome
regions. Using a χ2 test, we reject the null hypothesis that
IBD and non-IBD chromosome regions are equally likely
to carry at least one allele (P = 5.63 × 10–11) indicating the
presence of risk variants at this locus.
Results
We proposed a new gene-based method for analyzing af-
fected sibpairs by comparing the risk alleles on shared IBD
chromosome regions with the risk alleles on nonshared IBD
chromosome regions. We evaluated the proposed TRAFIC
design assuming a collapsing gene-based test by modeling al-
lelic heterogeneity at the locus of interest based on a summed
allele frequency of all risk variants f and a distribution of ef-
fect sizes with mean μ and variance σ2. For comparison, we
also evaluated the conventional cases-control design (con-
ventional) and a case-control design in which the cases are
selected conditional on having an affected sibling (selected
cases) under the same geneticmodel. For all three designs, we
assumed equal number of sequenced or genotyped individ-
uals. To use consistent language, we referred to shared IBD
chromosome regions in TRAFIC as cases and to nonshared
IBD chromosome regions as controls.
First, we compared the expected summed minor allele
frequency (sMAF) in cases and controls with and without
allelic heterogeneity to illustrate how TRAFIC behaved
relative to the conventional and selected cases designs. We
then calculated the analytical power of three designs. We also
evaluated robustness to population stratification. Finally, we
calculated the analytical power of TRAFIC while considering
different directions of gene-gene interaction.
Frequency Distribution of Risk Variants
To quantify the enrichment of risk variants in TRAFIC,
we calculated the expected sMAF of risk variants in cases
and controls of TRAFIC for a range of genetic models (see
supplementary Appendix 3 for details). Initially, we modeled
a locus with constant genetic risk μ between 1 and 5 for all
variants (σ2 = 0) (Fig. 1) and a disease prevalence of 0.01. In
TRAFIC (Fig. 1A), sMAF increased rapidly in cases (shared
IBD chromosome regions) and also increased roughly
linearly with μ in controls (nonshared IBD chromosome re-
gions). In the conventional design (Fig. 1B), sMAF increased
in cases almost linearly with relative risk, only slightly faster
than the sMAF in controls of TRAFIC. In the selected
cases design (Fig. 1C), sMAF in cases with affected siblings
increased faster than cases in the conventional case-control
design but slower than sMAF in cases of TRAFIC. Both in
the conventional design and selected cases design, sMAF in
controls decreased slightly asμ increased, especially formore
common variants (f = 0.20). As a result, TRAFIC generated
a larger difference in sMAF between cases and controls than
the conventional case-control design inmodels with f = 0.01
and 0.05. This advantage of TRAFIC reduced with increasing
f. For μ = 2, the difference in sMAF of TRAFIC compared to
the conventional design was 190% (0.019–0.010) at f = 0.01
and reduced to 123% (0.166–0.135) at f = 0.20. For a higher
disease prevalence of 0.20, the sMAF in controls decreased
more rapidly as μ increased and the difference between
cases and controls grew further in the conventional case-
control and selected cases design (supplementary Appendix
Fig. S2).
To evaluate scenarios where genetic effect differs between
risk variants, we considered a distribution of relative risks
with σ2 > 0 while maintaining μ = 1.5 (Fig. 2); for f = 0.01,
a value σ2 = 0.1 represents, for example, a scenario of 20
tested variants with equal frequencies where 6 of the tested
variants are nonfunctional (relative risk = 1) and 14 of the
tested variants have a relative risk of 1.71. A value σ2 = 0.2
would, for example, represent 9 nonfunctional variants and
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Figure 1. Summed minor allele frequency (sMAF) of risk variants in cases (solid lines) and controls (broken lines) under different study designs.
We show sMAF as a function of mean relative risk of risk variants for (A) TRAFIC, (B) the conventional case-control design, and (C) the selected
cases design for summed allele frequencies (f) of 0.01, 0.05, and 0.2 and fixed variance of relative risk σ 2 = 0.
Figure 2. Summed minor allele frequency (sMAF) of risk variants in cases (solid lines) and controls (broken lines) under different study designs.
We show sMAF as a function of variance of relative risk between risk variants for (A) TRAFIC, (B) the conventional case-control design, and (C)
the selected cases design for summed allele frequencies (f) of 0.01, 0.05, and 0.2 and fixed mean relative risk μ = 1.5.
11 variants with relative risk 1.91. Increasing σ2 did not affect
sMAF in cases or controls in the conventional design, as in
this design sMAFs only depended onμ (Fig. 2B). In TRAFIC,
sMAF in cases increased with σ2 while the sMAF in controls
remained constant. Similarly, in the selected cases design,
sMAF in cases increased with σ2, albeit more slowly than for
TRAFIC (Fig. 2A and C). Even if the average effect of risk
variants is 1 (μ = 1), the difference in sMAF between cases
and control increases with growing σ2 for TRAFIC and for
the selected cases design (supplementary Appendix Fig. S3).
Power Analysis
Based on the differences in expected sMAF, we calculated
the analytical power for three study designs for the same
number of individuals (n = 2,000): (1) 1,000 affected sib-
pairs using TRAFIC, (2) 1,000 cases and 1,000 controls in the
conventional cases-control design, and (3) 1,000 cases with
affected siblings and 1,000 controls in the selected cases de-
sign. Thus, we generated 4,000 independent observations for
the conventional and the selected design, and 3,000 inde-
pendent observations (1,000 cases and2,000 controls) for
TRAFIC. We also determined power empirically using simu-
lations and observed no difference between empirical power
and analytical power (supplementary Appendix Fig. S4).
Assuming all risk variants had the same relative risk be-
tween 1 and 5 (σ2 = 0), the selected cases design was uni-
formly most powerful (Fig. 3A) while the power ranking
of TRAFIC and the conventional design depended on f.
For rarer risk variants (f < 0.05), TRAFIC had substantially
higher power than the conventional design across all rela-
tive risks analyzed. For example, for f = 0.01 and μ = 2.5,
the power of the conventional design was 0.131 compared to
0.532 for TRAFIC.With increasing f or increasing prevalence,
the power difference between TRAFIC and the conventional
design reduced. For sets of risk variants with f > 0.05, the
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Figure 3. The analytical power curve for TRAFIC, conventional case-control, and selected cases design for different summed allele frequencies
(f). Row (A) displays the power as a function of mean relative risk evaluated at variance of relative risk σ 2 = 0. Row (B) shows the power as a
function of variance of relative risk evaluated at mean relative risk μ = 1.5. Results are shown for 2,000 individuals (1,000 sibpairs or 1,000 cases
and 1,000 controls) at a significance level 2.5 × 10−6.
power of the conventional design was larger than the power
of TRAFIC. The ranking of TRAFIC with the conventional
design depended on the prevalence of the disease, for preva-
lence 0.20, the conventional design was already more pow-
erful than TRAFIC for f > 0.01 (supplementary Appendix
Fig. S5).
In models with allelic heterogeneity (σ2 > 0), power
of TRAFIC increased with rising σ2 while the power of
the conventional design was independent of σ2 and only
depended on f (Fig. 3B). For f = 0.01 and 0.05 at μ = 1.5,
the power of TRAFIC was uniformly greater than the power
of the conventional design. For f = 0.2, TRAFIC was more
powerful than the conventional design for σ2 > 0.1. Even
for high-prevalence diseases, TRAFIC is more powerful than
the conventional design at modest levels of heterogeneity
(supplementary Appendix Fig. S5). Moreover, the selected
cases design was no longer uniformly most powerful in the
presence of moderate allelic heterogeneity. For example,
when f = 0.01 and σ2 = 2, TRAFIC outperformed the
selected cases design (with power of 0.412 and 0.306, respec-
tively). For amodel with nomean effect (μ = 1), TRAFICwas
uniformly most powerful regardless of f (results not shown).
Population Stratification
We modeled the level of population stratification by the
parameter π that represents the ratio of prevalence between
two populations (seeMaterials andMethods). In the absence
of true risk variants (μ = 1, σ2 = 0), the conventional case-
control design and the selected cases design only achieved the
nominal false-positive rate at π = 1 where equal proportion
of cases and controls are sampled from the two populations.
Both designs showed substantially increased false-positive
rate when moving away from π = 1. Especially, the selected
cases design showed a high false-positive rate for moderate
levels of stratification. For π = 1.22, the false-positive rate
was 0.064 and 0.107 for the conventional case-control and
selected cases designs; the inflation increased to 0.725 and
0.973 when π = 4.06. TRAFIC maintained the false-positive
rate at the nominal level of 0.05 across the range of π (Fig.
4) as long as we assumed either no linkage signal or a linkage
signal of the same strength in the two populations. If we
model a strong linkage signal in only one of the populations,
we observe a slightly increased false-positive rate in TRAFIC
(supplementary Appendix 5).
Gene-Gene Interaction
We summarized the effect of the gene-gene interaction
in a two-locus model by the parameter γ (see Materials
and Methods) and quantified the joint effect of both loci
on the disease heritability by sibling relative risk (SRR)
(see supplementary Appendix 4). To ensure comparability
across values of γ, we fixed the marginal relative risk at the
locus of interest, and adjusted the marginal effect at the
“remaining genome” locus to maintain SRR at 2, 4, and 8.
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Figure 4. False-positive rate in the presence for population stratification for TRAFIC, selected cases, and the conventional case-control design.
The false-positive rate is shown as a function of the prevalence ratio π between two sampled populations. Calculations are based on a summed
allele frequency of 0.01 in population 1 and 0.05 in population 2, and a sample size of 2,000 individuals (1,000 sibpairs or 1,000 cases and 1,000
controls) at a significance level 0.05.
We considered a locus of interest with f = 0.01 and set the
marginal relative risk to 2.2 for models with no interaction
(γ = 1) or synergistic interaction (γ > 1), and to 2.8 for
models with antagonistic interaction (γ < 1) to illustrate the
effect of antagonistic interaction with reasonable power. The
qualitative impact of interaction on power was independent
of these specific parameter choices (results not shown).
Because the marginal effect at the locus of interest was
constant, the power of the conventional case-control study
was not affected by the considered interaction or by SRR.
The power of TRAFIC increased with γ regardless of SRR
across most interaction parameters considered (Fig. 5). For
synergistic interaction, the power rose quickly with γ; the
exact trajectory depended on SRR of the model. The power
for models with a higher SRR increased faster for a lower γ,
but the rate of increase also decreased faster for a higher SRR.
Hence, models with a lower SRR reached maximal power
faster. In models of antagonistic interaction (γ < 1), TRAFIC
rapidly lost power with decreasing γ. This loss of power was
particularly pronounced for highly heritable disease (SRR =
8). For SRR at 2, 4, and 8, TRAFIC was less powerful than the
conventional design for γ < 0.52, 0.74, and 0.76, respectively
(Fig. 5A). However, the power started to increase when γ <
0.38, 0.31, and 0.26 for SRR = 2, 4, and 8, respectively. For
this extreme model of antagonistic interaction, a variant that
was causal in a population sample had a protective effect in
a family sample. Hence, the MAF on shared chromosome
regions became lower than the MAF on nonshared chromo-
some regions, generating power in a test for association.
Discussion
We introduce a new framework for gene-based association
tests of rare variants leveraging affected sibpairs (TRAFIC).
We compare the number of risk alleles located on chromo-
some regions shared IBD in an affected sibpair to the number
of risk alleles located on chromosome regions that are not
shared IBD. TRAFIC compares “cases” and “controls” within
a sibpair as a matched design and is thus generally robust to
population stratification. The test evaluates the null hypoth-
esis of no association and can therefore generate a signal only
in the presence of association and is powerful in the absence
of linkage.
The proposed design of taking shared chromosome regions
as new “cases” and nonshared chromosome regions as new
“controls” can be applied to any published gene-based test.
In this study, we evaluated the design for a collapsing gene-
based test as the power of this test can be calculated without
specifyingMAFor effect size distribution of each risk variant,
and it is therefore easier to obtain general conclusions. How-
ever, TRAFIC can also be applied to dispersion tests such as
SKAT [Wu et al., 2011].
We calculate the power of this new method using a general
model for risk variants, which is specified by the summed
allele frequency of risk variants, and mean and variance of
relative risk for risk variants. We compared three study de-
signs: (1) TRAFIC, (2) the conventional design of cases and
controls, and (3) a design where cases are enriched for rare
variants by selecting case individuals with affected relatives
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Figure 5. Analytical power of TRAFIC and the conventional case-control design under different models of gene-gene interaction. The horizontal
axis displays the interaction parameter γ ; gray and black lines represent different overall heritability parameterized as sibling relative risk (SRR).
Panel (A) represents the result for antagonistic interaction (γ < 1); panel (B) represents the result of synergistic interaction (γ > 1). Results are
shown for 2,000 individuals (1,000 sibpairs or 1,000 cases and 1,000 controls) at a significance level 2.5 × 10−6.
assuming the same number of sequenced/genotyped sam-
ples. For diseases with prevalence1% and in the absence of
gene-gene interaction, TRAFIC was more powerful than the
conventional case-control design for variants with summed
risk allele frequency less than 0.05, even though the con-
ventional case-control design contained more independent
observations. This power gain has two drivers. First, families
ascertained to carry multiple affected individuals are more
likely to segregate risk variants than random cases [Finger-
lin et al., 2004; Peng et al., 2010; Zo¨llner, 2012]. Second, if
such risk variants are rare, the founders of the pedigree are
likely to only carry one copy. As the probability of carrying
the risk variant is increased for each affected family member,
this variant is more likely to be located on a shared chromo-
some. With increasing allelic heterogeneity, the probability
for both affected siblings sharing an allele with a large effect
size also rises, increasing the number of risk alleles located on
shared IBD chromosome regions. Hence in the presence of
allelic heterogeneity, the power of TRAFIC increased, while
the power of the conventional case-control design was un-
changed.
The power of a family-based design also depends on the
interaction between variants at the locus of interest and the
remaining genome. Sampling from families withmultiple af-
fected individuals increases the overall genetic load for all
cases. Hence, if the genetic effect at the locus of interest in-
creases with overall genetic load, the power advantage of
family-based designs over population-based designs is larger
than under a model of no interaction. On the other hand, if
the genetic effect of risk variants at the locus of interest de-
creases with overall genetic load, the power in family-based
designs is smaller than the power under a model of no inter-
action and population-based designs can be more powerful.
This effect has been described before for additive gene-gene
interaction,which is a special case of genetic effect at the locus
of interest decreasing with overall genetic load [Helbig et al.,
2013; Ionita-Laza and Ottman, 2011; Risch, 2001; Zo¨llner,
2012].
Moreover,TRAFFIC is generally robust topopulation strat-
ification, as it compares IBD chromosome regions to non-
shared chromosome regions in every sibpair thus naturally
matching the genetic background of samples. This robust-
ness can be violated in regions where one of the populations
has a strong linkage signal while the other population has
no evidence for linkage. However, this unlikely scenario only
results in minor increase of the false-positive rate and has
thus little impact on the utility of our method. As the efficacy
of current methods to control for population stratification
in population-based designs for rare variant tests is not clear
[Mathieson andMcVean, 2012, Liu,Nicolae andChen, 2013],
family-based designs may be necessary to avoid spurious as-
sociation. TRAFIC achieves this robustness to stratification
by using nonshared chromosome regions as controls at the
cost of some reduction in power. As nonshared chromosome
regions have a higher risk allele frequency than chromo-
some regions in population controls, a test comparing shared
chromosome regions against chromosome regions from un-
affected controls may be more powerful than TRAFIC. How-
ever, such a design would be very susceptible to population
stratification, evenmore than the selected cases design shown
in Figure 4.
In conclusion, we have proposed TRAFIC using affected
sibpairs for testing the association between a set of rare vari-
ants and the disease phenotype. TRAFIC is more powerful
than the conventional case-control design under awide range
of models while being generally robust to population strati-
fication.
Web Resources
The R code and manual for TRAFIC can be downloaded
from http://www-personal.umich.edu/khlin/.
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